Post-Marketing surveillance for HPV infection related serious disease in a cohort of Chinese women who received GARDASIL® and GARDASIL®9 (V503-107) First published 19/11/2026 Last updated 19/11/2026 EU PAS number:EUPAS1000001165 Study Planned
Merck Sharp & Dohme LLC United States First published:01/02/2024 Last updated 08/07/2025 Institution Pharmaceutical company
Clinical Trials Disclosure Merck Sharp & Dohme LLC ClinicalTrialsDisclosure@msd.comStudy contactClinicalTrialsDisclosure@msd.com